Trials / Completed
CompletedNCT03556904
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE): A Phase II Randomized Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- University of Michigan Rogel Cancer Center · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial will determine whether the addition of radiotherapy to standard of care systemic therapy improves objective progression-free survival compared to systemic therapy alone in patients with oligometastatic castration-resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Ablative Radiation Therapy | Radiotherapy will typically be delivered to a total EQD2 (Equivalent dose in 2Gy fractions) that ranges between conventional 30 Gy in 10 fractions, to SBRT (Stereotactic Body Radiation Therapy) with 50 Gy in 5 fractions. |
| DRUG | Hormone therapy or chemotherapy | Current standard of care dosing with standard agents; hormone therapy or chemotherapy. |
Timeline
- Start date
- 2018-12-10
- Primary completion
- 2023-07-28
- Completion
- 2023-07-28
- First posted
- 2018-06-14
- Last updated
- 2026-01-15
- Results posted
- 2026-01-15
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03556904. Inclusion in this directory is not an endorsement.